OVERALL SURVIVAL (OS) AND PROGRESSION FREE SURVIVAL (PFS) RESULTS FOR A RANDOMIZED PHASE 2 TRIAL OF IPILIMUMAB (IPI) AND PACLITAXEL/CARBOPLATIN (P/C) IN FIRST-LINE STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Lynch, T. J., Jr. [1 ]
Neal, J. [2 ]
Bondarenko, I. [3 ]
Luft, A. [4 ]
Serwatowski, P. [5 ]
Barlesi, F. [9 ]
Chacko, R. [10 ]
Sebastian, M. [6 ]
Cuillerot, J. [7 ]
Reck, M. [8 ]
机构：
[1] Yale Univ, Ctr Canc, New Haven, CT USA
[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA
[3] Dnipropetrovsk Municipal Clin Hosp 4, Dept Oncol Radiodiagnosis & Radioth, Dnepropetrovsk, Ukraine
[4] Leningrad Reg Clin Hosp, State Inst, St Petersburg, Russia
[5] Oddzial Chemioterapii, Szczecin, Poland
[6] Johannes Gutenberg Univ Mainz, Mainz, Germany
[7] Bristol Myers Squibb Co, Global Clin Res, Wallingford, CT 06492 USA
[8] Hosp Grosshansdorf, Grosshansdorf, Germany
[9] Univ Mediterranee Assistance Publ Hapitaux Marsei, Marseille, France
[10] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：126 / 126
页数：1
相关论文
共 50 条
  • [41] Phase I-II trial of TLK286 (telcyta), carboplatin (C), and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC)
    Sequist, L
    Fidias, P
    Temel, J
    Kennedy, E
    Ostler, P
    Rabin, M
    Huberman, M
    Keck, J
    Brown, G
    Lynch, T
    LUNG CANCER, 2005, 49 : S269 - S269
  • [42] Impact of dose reductions of platinum compounds on survival in stage IIIB/IV non-small cell lung cancer (NSCLC)
    Yumuk, P. F.
    Teomete, M.
    Dane, F.
    Cabuk, D.
    Basaran, G.
    Turhal, N. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [43] PHASE II RANDOMIZED, OPEN-LABEL STUDY OF CETUXIMAB (CET) AND BEVACIZUMAB (BEV) IN COMBINATION WITH PACLITAXEL (P) AND CARBOPLATIN (C) IN PATIENTS WITH STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC)
    Bonomi, Philip
    Mace, Joseph
    Mandana, Romeo
    Min, Myo
    Mark, Olsen
    Youssoufian, Hagop
    Katz, Terry
    Simms, Lorinda
    Lee, Hyun Jung
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1292 - S1292
  • [44] Impact Of Bronchoscopy After First-Line Chemotherapy In Patients With Stage Iv Non Small Cell Lung Cancer On Overall Survival
    Dayen, C.
    Trouve, C.
    Poulet, C.
    Gubler, B.
    Sevestre, H.
    Suguenot, R.
    Bentayeb, H.
    Rault, I.
    Lecuyer, E.
    Hoguet, E.
    Le Meunier, F.
    Jounieaux, V.
    Benzerdjeb, N.
    Andrejak, C.
    Douadi, Y.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [45] Hospitalization for immune related toxicity and overall survival (OS) among patients with metastatic non-small cell lung cancer (NSCLC) treated with first-line pembrolizumab
    Khorasanchi, Adam
    Zhao, Songzhu
    Wei, Lai
    Li, Mingjia
    Ho, Kevin
    Abu-Sbeih, Hamzah
    Alexander, John Howard
    Goodyear, Evelyn
    Secor, Austin
    Shields, Peter G.
    He, Kai
    Kaufman, Jacob
    Memmott, Regan Michelle
    Alahmadi, Asrar
    Carbone, David Paul
    Otterson, Gregory Alan
    Meara, Alexa Simon
    Presley, Carolyn J.
    Owen, Dwight Hall
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] A phase I study of paclitaxel in combination with etoposide in patients with stage IIIB/IV non-small cell lung cancer (NSCLC)
    Ukena, D
    Berg, M
    Leutz, M
    Zell, L
    Schlimmer, P
    Sybrecht, GW
    LUNG CANCER, 1998, 19 (01) : 31 - 36
  • [47] A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
    Crawford, Jeffrey
    Swanson, Paul
    Schwarzenberger, Paul
    Sandler, Alan
    Prager, Diane
    Zhang, Kathy
    Freeman, Daniel J.
    Johnson, Carol W.
    Krishnan, Kartik
    Johnson, David
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (12) : 1510 - 1518
  • [48] SIMPLE MULTIPLES OF MEDIAN OVERALL SURVIVAL (OS) MAY NOT ESTIMATE SURVIVAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH FIRST-LINE EGFR-TARGETED AGENTS
    Lerner, A.
    Williams, M.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S75 - S76
  • [49] Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study (vol 30, pg 2046, 2012)
    Lynch, T. J.
    Bondarenko, I
    Luft, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (29) : 3654 - 3654
  • [50] Randomized phase II trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage IIIb/IV nonsquamous non-small cell lung cancer (NSCLC): The FALCON trial
    Garon, E. B.
    Kabbinavar, F. F.
    Neidhart, J. A.
    Neidhart, J. D.
    Gabrail, N. Y.
    Oliveira, M. R.
    Lu, S. P.
    Balkissoon, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345